Defining the patient at high risk for melanoma

International Journal of Dermatology

Volumn 49, Issue 4, 2010, Pages 362-376

  Psaty, Estee L ^a   Scope, Alon ^a   Halpern, Allan C ^a   Marghoob, Ashfaq A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGE; ANAMNESIS; CANCER RISK; CANCER SCREENING; CLINICAL FEATURE; EARLY DIAGNOSIS; EPILUMINESCENCE MICROSCOPY; FAMILY HISTORY; GENETIC SUSCEPTIBILITY; HIGH RISK PATIENT; HUMAN; MELANOMA; NEVUS; PHENOTYPE; REVIEW; SELF EXAMINATION; SEX DIFFERENCE; SKIN EXAMINATION; STRATIFICATION; SUN EXPOSURE; SYMPTOMATOLOGY; ULTRAVIOLET RADIATION;

DYSPLASTIC NEVUS SYNDROME; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MASS SCREENING; MELANOMA; NEVUS, PIGMENTED; RISK ASSESSMENT; RISK FACTORS; SKIN DISEASES; SKIN PIGMENTATION; SUNBATHING; ULTRAVIOLET RAYS;

EID: 77952100805     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2010.04381.x     Document Type: Review

References (123)

1. Jemal A, Siegel R, Ward E. Cancer statistics, 2008. CA Cancer J Clin 2008, 58(2):71-96. 10.3322/CA.2007.0010, DOI
2. Jemal A, Clegg LX, Ward E. Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer 2004, 101:3-27.
3. Screening for skin cancer: recommendations and rationale. Am J Prev Med 2001, 20(Suppl 3):44-46.
4. Federman DG, Kravetz JD, Kirsner RS. Skin cancer screening by dermatologists: prevalence and barriers. J Am Acad Dermatol 2002, 46:710-714.
5. Aitken JF. Increase in skin cancer screening during a community-based randomized intervention trial. Int J Cancer 2006, 118:1010-1016.
6. Janda M. Do centralised skin screening clinics increase participation in melanoma screening (Australia)? Cancer Causes Control 2006, 17:161-168.
7. Losina E. Visual screening for malignant melanoma: a cost-effectiveness analysis. Arch Dermatol 2007, 143:21-28.
8. Halpern AC, Lieb JA. Early melanoma diagnosis: a success story that leaves room for improvement. Curr Opin Oncol 2007, 19:109-115.
9. Baumert J. Factors associated with a high tumour thickness in patients with melanoma. Br J Dermatol 2007, 156:938-944.
10. Geller AC. The first 15 years of the American Academy of Dermatology skin cancer screening programs: 1985-1999. J Am Acad Dermatol 2003, 48:34-41.
11. Liu W. Rate of growth in melanomas: characteristics and associations of rapidly growing melanomas. Arch Dermatol 2006, 142:1551-1558.
12. Geller AC. Use of health services before the diagnosis of melanoma: implications for early detection and screening. J Gen Intern Med 1992, 7:154-157.
13. Rigel DS. Importance of complete cutaneous examination for the detection of malignant melanoma. J Am Acad Dermatol 1986, 14:857-860.
14. Koh HK. Melanoma screening: focusing the public health journey. Arch Dermatol 2007, 143:101-103.
15. Hester EJ. Demand outstrips supply of US pediatric dermatologists: results from a national survey. J Am Acad Dermatol 2004, 50:431-434.
16. Resneck JS, Kimball AB. Who else is providing care in dermatology practices? Trends in the use of nonphysician clinicians. J Am Acad Dermatol 2008, 58:211-216.
17. Resneck JS, Lipton S, Pletcher MJ. Short wait times for patients seeking cosmetic botulinum toxin appointments with dermatologists. J Am Acad Dermatol 2007, 57:985-989.
18. Jackson A. Can primary prevention or selective screening for melanoma be more precisely targeted through general practice? A prospective study to validate a self administered risk score. BMJ 1998, 316:34-38. Discussion 38-9
19. Freiman A. Impact of melanoma diagnosis on sun-awareness and protection: efficacy of education campaigns in a high-risk population. J Cutan Med Surg 2004, 8:303-309.
20. Masri GD. Screening and surveillance of patients at high risk for malignant melanoma result in detection of earlier disease. J Am Acad Dermatol 1990, 22:1042-1048.
21. Williams HA. Evaluating the usefulness of self-reported risk factors in a skin cancer screening program. Melanoma Res 2006, 16:341-345.
22. Melia J. Feasibility of targeted early detection for melanoma: a population-based screening study. Br J Cancer 2000, 82:1605-1609.
23. Harbauer A. Validity of an unsupervised self-administered questionnaire for self-assessment of melanoma risk. Melanoma Res 2003, 13:537-542.
24. Eiser JR. Is targeted early detection for melanoma feasible? Self assessments of risk and attitudes to screening. J Med Screen 2000, 7:199-202.
25. Lawson DD. Nevus counting as a risk factor for melanoma: comparison of self-count with count by physician. J Am Acad Dermatol 1994, 31:438-444.
26. Stam-Posthuma JJ. Multiple primary melanomas. J Am Acad Dermatol 2001, 44:22-27.
27. Ferrone CR. Clinicopathological features of and risk factors for multiple primary melanomas. JAMA 2005, 294:1647-1654.
28. Kang S. Multiple primary cutaneous melanomas. Cancer 1992, 70:1911-1916.
29. Fisher NM. Breslow depth of cutaneous melanoma: impact of factors related to surveillance of the skin, including prior skin biopsies and family history of melanoma. J Am Acad Dermatol 2005, 53:393-406.
30. Marghoob AA. Risk of developing multiple primary cutaneous melanomas in patients with the classic atypical-mole syndrome: a case-control study. Br J Dermatol 1996, 135:704-711.
31. McKinnon JG. Prognosis for patients with thin cutaneous melanoma: long-term survival data from New South Wales Central Cancer Registry and the Sydney Melanoma Unit. Cancer 2003, 98:1223-1231.
32. Gimotty PA. A population-based validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2005, 23:8065-8075.
33. Marghoob AA. Basal cell and squamous cell carcinomas are important risk factors for cutaneous malignant melanoma. Screening implications. Cancer 1995, 75(2 Suppl):707-714.
34. Gandini S. Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors. Eur J Cancer 2005, 41:2040-2059.
35. Pielop JA, Brownell I, Duvic M. Mycosis fungoides associated with malignant melanoma and dysplastic nevus syndrome. Int J Dermatol 2003, 42:116-122.
36. Lynch HT, Krush AJ. Heredity and malignant melanoma: implications for early cancer detection. Can Med Assoc J 1968, 99:17-21.
37. High WA, Robinson WA. Genetic mutations involved in melanoma: a summary of our current understanding. Adv Dermatol 2007, 23:61-79.
38. Weinstock MA, Brodsky GL. Bias in the assessment of family history of melanoma and its association with dysplastic nevi in a case-control study. J Clin Epidemiol 1998, 51:1299-1303.
39. Jackson A, Wilkinson C, Pill R. Moles and melanomas - who's at risk, who knows, and who cares? A strategy to inform those at high risk. Br J Gen Pract 1999, 49:199-203.
40. Greene MH. High risk of malignant melanoma in melanoma-prone families with dysplastic nevi. Ann Intern Med 1985, 102:458-465.
41. Tucker MA. Risk of melanoma and other cancers in melanoma-prone families. J Invest Dermatol 1993, 100:350S-355S.
42. Fusaro RM, Lynch HT. The FAMMM syndrome: epidemiology and surveillance strategies. Cancer Invest 2000, 18:670-680.
43. Florell SR. Population-based analysis of prognostic factors and survival in familial melanoma. J Clin Oncol 2005, 23:7168-7177.
44. Leachman SA, Carruci J, Kohlmann W. Selection criteria for genetic assessment of patients with familial melanoma. J Am Acad Dermatol. 2009, 61(4):677.e1-14. Oct
45. Lynch HT. Familial atypical multiple mole-melanoma (FAMMM) syndrome: segregation analysis. J Med Genet 1983, 20:342-344.
46. Lynch HT. Phenotypic variation in eight extended CDKN2A germline mutation familial atypical multiple mole melanoma-pancreatic carcinoma-prone families: the familial atypical mole melanoma-pancreatic carcinoma syndrome. Cancer 2002, 94:84-96.
47. Hemminki K, Zhang H, Czene K. Familial and attributable risks in cutaneous melanoma: effects of proband and age. J Invest Dermatol 2003, 120:217-223.
48. Begg CB. Familial aggregation of melanoma risks in a large population-based sample of melanoma cases. Cancer Causes Control 2004, 15:957-965.
49. Ries LAG. SEER Cancer Statistics Review, 1975-2004, National Cancer Institute 2007, http://seer.cancer.gov/csr/1975_2004/results_merged/topic_med_age.pdf, Bethesda, MD, , based on November 2006 SEER data submission, posted to the SEER web site, 2007
50. Jemal A. Cancer statistics, 2008. CA Cancer J Clin 2008, 58:71-96.
51. Chamberlain AJ. Nodular type and older age as the most significant associations of thick melanoma in Victoria, Australia. Arch Dermatol 2002, 138:609-614.
52. Geller AC. Screening, early detection, and trends for melanoma: current status (2000-2006) and future directions. J Am Acad Dermatol 2007, 57:555-572. Quiz 573-6
53. Janda M. What motivates men age > or = 50 years to participate in a screening program for melanoma? Cancer 2006, 107:815-823.
54. Aitken JF. Clinical outcomes from skin screening clinics within a community-based melanoma screening program. J Am Acad Dermatol 2006, 54:105-114.
55. Tsang MW, Resneck JS. Even patients with changing moles face long dermatology appointment wait-times: a study of simulated patient calls to dermatologists. J Am Acad Dermatol 2006, 55:54-58.
56. Negin BP. Symptoms and signs of primary melanoma: important indicators of Breslow depth. Cancer 2003, 98:344-348.
57. Graves J, Fleischman MH, Goldstein GD. Derm Access: a new triage system to rapidly identify suspicious skin lesions. Dermatol Surg 2006, 32:1486-1490.
58. Tucker MA. Clinically recognized dysplastic nevi. A central risk factor for cutaneous melanoma. JAMA 1997, 277:1439-1444.
59. Elwood JM, Jopson J. Melanoma and sun exposure: an overview of published studies. Int J Cancer 1997, 73:198-203.
60. Gandini S. Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. Eur J Cancer 2005, 41:45-60.
61. Kricker A. Ambient UV, personal sun exposure and risk of multiple primary melanomas. Cancer Causes Control 2007, 18:295-304.
62. Elwood JM. Etiological differences between subtypes of cutaneous malignant melanoma: Western Canada Melanoma Study. J Natl Cancer Inst 1987, 78:37-44.
63. Green A. Sun exposure, skin cancers and related skin conditions. J Epidemiol 1999, 9(6 Suppl):S7-S13.
64. Spencer JM, Amonette RA. Indoor tanning: risks, benefits, and future trends. J Am Acad Dermatol 1995, 33:288-298.
65. The association of use of sunbeds with cutaneous malignant melanoma and other skin cancers: a systematic review. Int J Cancer 2007, 120:1116-1122. 10.1002/ijc.22453, DOI
66. Stern RS, Nichols KT, Vakeva LH. Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). The PUVA Follow-Up Study. N Engl J Med 1997, 336:1041-1045.
67. Stern RS. The risk of melanoma in association with long-term exposure to PUVA. J Am Acad Dermatol 2001, 44:755-761.
68. McKenna DB. Evidence for an association between cutaneous malignant melanoma and lymphoid malignancy: a population-based retrospective cohort study in Scotland. Br J Cancer 2003, 88:74-78.
69. Brennan P. Second primary neoplasms following non-Hodgkin's lymphoma in New South Wales, Australia. Br J Cancer 2000, 82:1344-1347.
70. Levi F. Non-Hodgkin's lymphomas, chronic lymphocytic leukaemias and skin cancers. Br J Cancer 1996, 74:1847-1850.
71. Travis LB. Second cancers following non-Hodgkin's lymphoma. Cancer 1991, 67:2002-2009.
72. Travis LB. Second cancers in patients with chronic lymphocytic leukemia. J Natl Cancer Inst 1992, 84:1422-1427.
73. Jensen P. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol 1999, 40:177-186.
74. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med 2003, 348:1681-1691.
75. Kraemer KH. Xeroderma pigmentosum and related disorders: examining the linkage between defective DNA repair and cancer. J Invest Dermatol 1994, 103(5 Suppl):96S-101S.
76. Easton D. Cancer risks in BRCA2 mutation carriers. The Breast Cancer Linkage Consortium. J Natl Cancer Inst 1999, 91:1310-1316.
77. Goggins W, Gao W, Tsao H. Association between female breast cancer and cutaneous melanoma. Int J Cancer 2004, 111:792-794.
78. Bevona C. Cutaneous melanomas associated with nevi. Arch Dermatol 2003, 139:1620-1624. Discussion 1624
79. Tsao H. The transformation rate of moles (melanocytic nevi) into cutaneous melanoma: a population-based estimate. Arch Dermatol 2003, 139:282-288.
80. Cohen MH. Surgical prophylaxis of malignant melanoma. Ann Surg 1991, 213:308-314.
81. Kelly JW. A high incidence of melanoma found in patients with multiple dysplastic naevi by photographic surveillance. Med J Aust 1997, 167:191-194.
82. Augustsson A. Common and dysplastic naevi as risk factors for cutaneous malignant melanoma in a Swedish population. Acta Derm Venereol 1991, 71:518-524.
83. Garbe C. Risk factors for developing cutaneous melanoma and criteria for identifying persons at risk: multicenter case-control study of the Central Malignant Melanoma Registry of the German Dermatological Society. J Invest Dermatol 1994, 102:695-699.
84. Garbe C. Markers and relative risk in a German population for developing malignant melanoma. Int J Dermatol 1989, 28:517-523.
85. Grob JJ. Count of benign melanocytic nevi as a major indicator of risk for nonfamilial nodular and superficial spreading melanoma. Cancer 1990, 66:387-395.
86. Halpern AC. Dysplastic nevi as risk markers of sporadic (nonfamilial) melanoma. A case-control study. Arch Dermatol 1991, 127:995-999.
87. Holly EA. Number of melanocytic nevi as a major risk factor for malignant melanoma. J Am Acad Dermatol 1987, 17:459-468.
88. MacKie RM, Aitchison TC, Freudenberger T. Risk factors for melanoma. Lancet 1989, 2:928.
89. Roush GC. Independence of dysplastic nevi from total nevi in determining risk for nonfamilial melanoma. Prev Med 1988, 17:273-279.
90. Swerdlow AJ. Benign melanocytic naevi as a risk factor for malignant melanoma. Br Med J (Clin Res Ed) 1986, 292:1555-1559.
91. Gandini S. Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi. Eur J Cancer 2005, 41:28-44.
92. Arumi-Uria M, McNutt NS, Finnerty B. Grading of atypia in nevi: correlation with melanoma risk. Mod Pathol 2003, 16:764-771.
93. Shors AR. Dysplastic naevi with moderate to severe histological dysplasia: a risk factor for melanoma. Br J Dermatol 2006, 155:988-993.
94. Titus-Ernstoff L. Multiple primary melanoma: two-year results from a population-based study. Arch Dermatol 2006, 142:433-438.
95. Halpern AC. A cohort study of melanoma in patients with dysplastic nevi. J Invest Dermatol 1993, 100:346S-349S.
96. Krengel S, Hauschild A, Schafer T. Melanoma risk in congenital melanocytic naevi: a systematic review. Br J Dermatol 2006, 155:1-8.
97. Zaal LH. Risk of malignant transformation of congenital melanocytic nevi: a retrospective nationwide study from The Netherlands. Plast Reconstr Surg 2005, 116:1902-1909.
98. Marghoob AA. Congenital melanocytic nevi. Cancer of the Skin 2005, Rigel DS. In, eds, ?????, Elsevier Inc.
99. Banky JP. Incidence of new and changed nevi and melanomas detected using baseline images and dermoscopy in patients at high risk for melanoma. Arch Dermatol 2005, 141:998-1006.
100. Bauer J. Surveillance of patients at high risk for cutaneous malignant melanoma using digital dermoscopy. Br J Dermatol 2005, 152:87-92.
101. Robinson JK, Nickoloff BJ. Digital epiluminescence microscopy monitoring of high-risk patients. Arch Dermatol 2004, 140:49-56.
102. Hofmann-Wellenhof R. Influence of UVB therapy on dermoscopic features of acquired melanocytic nevi. J Am Acad Dermatol 1997, 37:559-563.
103. Nguyen TD. Ultraviolet radiation, melanocytic naevi and their dose-response relationship. Br J Dermatol 1997, 137:91-95.
104. Hofmann-Wellenhof R. Ultraviolet radiation of melanocytic nevi: a dermoscopic study. Arch Dermatol 1998, 134:845-850.
105. Rosario R. Histological changes produced in skin by equally erythemogenic doses of UV-A, UV-B, UV-C and UV-A with psoralens. Br J Dermatol 1979, 101:299-308.
106. Stanganelli I. Critical effects of intense sun exposure on the expression of epiluminescence microscopy features of acquired melanocytic nevi. Arch Dermatol 1997, 133:979-982.
107. Menzies SW. Short-term digital surface microscopic monitoring of atypical or changing melanocytic lesions. Arch Dermatol 2001, 137:1583-1589.
108. Kittler H. Identification of clinically featureless incipient melanoma using sequential dermoscopy imaging. Arch Dermatol 2006, 142:1113-1119.
109. Altamura D, Avramidis M, Menzies SW. Assessment of the optimal interval for and sensitivity of short-term sequential digital dermoscopy monitoring for the diagnosis of melanoma. Arch Dermatol 2008, 144(4):502-506. Apr
110. Ferrara G. Do we detect a new spectrum of biologically 'benign' melanomas in the dermoscopy era? Melanoma Res 2004, 14:567-568.
111. Cho E. Risk factors and individual probabilities of melanoma for whites. J Clin Oncol 2005, 23:2669-2675.
112. Cho E, Rosner BA, Colditz GA. Risk factors for melanoma by body site. Cancer Epidemiol Biomarkers Prev 2005, 14:1241-1244.
113. Fears TR. Identifying individuals at high risk of melanoma: a practical predictor of absolute risk. J Clin Oncol 2006, 24:3590-3596.
114. Whiteman DC. Anatomic site, sun exposure, and risk of cutaneous melanoma. J Clin Oncol 2006, 24:3172-3177.
115. Goldberg MS. Risk factors for presumptive melanoma in skin cancer screening: American Academy of Dermatology National Melanoma/Skin Cancer Screening Program experience 2001-2005. J Am Acad Dermatol 2007, 57:60-66.
116. Scope A. Predominant dermoscopic patterns observed among nevi. J Cutan Med Surg 2006, 10:170-174.
117. Zalaudek I. Nevus type in dermoscopy is related to skin type in white persons. Arch Dermatol 2007, 143:351-356.
118. Lipoff JB, Scope A, Dusza SW. Complex dermoscopic pattern: a potential risk marker for melanoma. Br J Dermatol 2008, 158(4):821-824. 10.1111/j.1365-2133-2007.08404.x, DOI
119. Scope A. The " ugly duckling" sign: agreement between observers. Arch Dermatol 2008, 144:58-64.
120. Kefford RF. Counseling and DNA testing for individuals perceived to be genetically predisposed to melanoma: a consensus statement of the Melanoma Genetics Consortium. J Clin Oncol 1999, 17:3245-3251.
121. Geller AC. A randomized trial to improve early detection and prevention practices among siblings of melanoma patients. Cancer 2006, 107:806-814.
122. Kraemer KH. The role of sunlight and DNA repair in melanoma and nonmelanoma skin cancer. The xeroderma pigmentosum paradigm. Arch Dermatol 1994, 130:1018-1021.
123. Goldstein AM. Genotype-phenotype relationships in U.S. melanoma-prone families with CDKN2A and CDK4 mutations. J Natl Cancer Inst 2000, 92:1006-1010.